Considering the available body of evidence, mobocertinib has demonstrated clinical activity in NSCLC harboring EGFR exon 20 insertion mutations, where efficacy has been historically low with other EGFR TKIs, albeit in different treatment line settings. This evidence concerns the gene EGFR and non-small cell lung carcinoma.